RAGNARTarlatamab with Chemotherapy in Advanced Neuroendocrine Carcinomas

This clinical trial focuses on advanced neuroendocrine carcinomas (NECs) of the digestive system or unknown primary origin, which are aggressive cancers that are difficult to treat. These tumors are quite rare, but their detection has increased thanks to better diagnostic tools. Currently, the main treatment for these tumors is chemotherapy, but it only provides limited benefits. The study explores whether tarlatamab, a drug that targets specific tumor markers, either alone or with a standard chemotherapy called FOLFIRI, can offer better outcomes for patients. The ultimate goal is to find an effective treatment option that could improve survival and quality of life for those affected by these challenging cancers. In this trial, participants are divided into two groups: one receives only tarlatamab, while the other receives tarlatamab along with FOLFIRI chemotherapy. The trial evaluates how long patients live without the cancer progressing and their overall survival over a year. Safety and potential side effects are closely monitored, with adjustments made to ensure participants' well-being. Regular imaging tests like CT or MRI scans assess the cancer's response to the treatment. Approximately 87 patients from hospitals in Spain and France will participate, and their quality of life is also evaluated throughout the study to ensure a comprehensive understanding of the treatment's impact.